Is Saxagliptin powder the "middle effective hypoglycemic representative" of DPP-4 inhibitor?

Saxagliptin powder belongs to selective DPP4 inhibitor oral hypoglycemic bulk drug, and the finished product is white crystalline powder, which competitively inhibits the activity of dipeptidyl peptidase 4 by virtue of the unique fused heterocyclic chemical configuration, prolongs the retention time of natural incretin in GLP‑1 and GIP in vivo, smoothly regulates fasting and postprandial blood glucose according to the law of blood glucose-dependent insulin secretion, and is not easy to induce adverse reactions related to hypoglycemia. It is the core raw material for the production of tablet preparations for type 2 diabetes, and it is also used for in vitro enzyme activity screening, compatibility of compound hypoglycemic preparations and pharmacopoeia calibration, and has a stable market demand in hypoglycemic raw materials and drugs for chronic diseases.

🔬Molecular archives of cyanopyrrolidine

Saxagliptin has a molecular formula of CHNO, with a molecular weight of 315.41. The molecular body is composed of pyrrolidine-azacycloheptane tricyclic fused mother nucleus, cyclopropamide side chain and adamantane substituted fragment. The nitrogen atom in the fused ring brings polar binding sites, and the rigid hydrophobic groups of side chain propyl and adamantane fill the hydrophobic cavity of DPP4 enzyme protein. The whole three-dimensional space configuration can be accurately embedded in the catalytic active region, which is the key structure to realize high-selective binding of target. The cyclic amine structure of fused ring can be slightly protonated in physiological and humoral environment, which optimizes the dissolution performance of API in gastrointestinal tract. The compact spatial structure of cyclopropyl further reduces the probability of molecular nonspecific binding, greatly reduces the inhibition on homologous proteases of DPP8 and DPP9, and reduces the probability of systemic adverse reactions from the molecular level.

The whole molecule has moderate fat solubility and weak hydrophilicity, the lipid-water partition coefficient meets the requirements of intestinal epithelial transmembrane transport, the chemical structure is stable under the condition of sealed storage at room temperature in the dark, and the amide bond will be hydrolyzed and broken only under the condition of long-term heating with strong acid and alkali. Neutral pharmaceutical excipients are selected for compatibility in preparation production to avoid the extreme pH environment from damaging the activity of raw materials. Medicinal refined Saxagliptin powder has fine and loose texture, no obvious odor, slightly soluble in pure water and almost insoluble in alkane grease solvents. The crude product was obtained by multi-step cyclization and acylation reaction in industrial preparation, and the purification was completed by fractional recrystallization with mixed solvent and decolorization with activated carbon. The HPLC purity of the finished product was stable above 99.5%, and all the heavy metals and residual solvents met the quality control standards of ICH raw materials for human use, which was suitable for mass production of solid preparations such as common oral tablets and dispersible tablets.

In stereochemistry, saxagliptin molecule contains many chiral centers and has clear absolute configuration. The complexity of its molecular structure endows it with high DPP-4 selectivity. Physically, Saxagliptin powder is usually supplied as white to white-like crystalline powder, and the purity requirement is not less than 99.0%. In terms of solubility, the compound is easily soluble in dimethyl sulfoxide, and its water solubility is moderate in the physiological pH range, which ensures the rapid dissolution of its oral preparation.

In terms of stability, API powder can be stored stably for 3 years at-20 C and 2 years at 4 C. The solution prepared with DMSO can be stored for 6 months at-80 C. The reference standard of European Pharmacopoeia requires that APIs be stored at 2-8 C, which belongs to controlled laboratory reference materials and is only used for testing specified in Pharmacopoeia. In terms of quality control, the key indicators of pharmacopoeia-grade APIs include content determination, related substances, moisture, residual solvents and enantiomeric purity.

Saxagliptin powder has multiple aliases in structural classification, and its unique FDA identification code is 9GB927LAJW. Its IUPAC name reflects its structural characteristics as a derivative of (1S,3S,5S)-2- azabicyclo [3.1.0] hexane -3- carbonitrile. In terms of intellectual property rights, the patent of the core compound of the drug has expired, which has promoted the rapid development of the generic drug market.

Delaying the hydrolysis of DPP4 to prolong the hypoglycemic effect of endogenous incretin.

The complete hypoglycemic effect of Saxagliptin powder is gradually promoted according to five physiological processes: competitive occupying of DPP4, in vivo accumulation of active incretin, glucose-dependent insulin release, inhibition of glucagon secretion, and long-term protection of islet cells. The drug effect follows the dynamic change of glucose concentration in the body, and when blood sugar falls back to the normal range, it will automatically slow down the hypoglycemic related regulation, thus avoiding the hidden danger of hypoglycemia caused by indiscriminate stimulation of insulin secretion from the pharmacological mechanism.

After oral administration into the blood, the drug directionally binds to the DPP4 catalytic sites in the circulation and intestinal distribution of the body, competitively occupies the substrate binding area, and directly blocks the hydrolysis and cleavage process of the GLP‑1 and GIP secreted by the intestinal tract after eating by DPP4. Under physiological conditions, the two kinds of oxytocin are inactivated by enzyme decomposition within a few minutes in the body, and the half-life of endogenous oxytocin is greatly prolonged after the raw materials effectively inhibit the enzyme activity, so that the original biological activity can be continuously maintained to participate in blood sugar regulation.

When the blood glucose concentration increases after a meal, the retained active incretin acts on islet β cells, inducing insulin synthesis and release as needed according to the actual blood glucose level, accelerating the uptake and utilization of glucose by peripheral muscles and adipose tissues, and stably depressing the peak blood glucose after a meal. After the blood glucose gradually decreases, the secreting signal is weakened synchronously, and it will not continue to stimulate insulin overproduction.

Active incretin acts on islet α cells at the same time, which inhibits the synthesis and release of glucagon. Glucagon can promote the decomposition of glycogen in the liver and then raise blood sugar. After the secretion of this hormone is inhibited, the endogenous glucose output in the liver decreases, which steadily improves the clinical manifestations of high fasting blood sugar.

Under the condition of long-term regular medication, the sustained and stable level of incretin can alleviate the persistent damage of islet β cells caused by high glucose toxicity and high lipid toxicity, gradually improve the impaired islet secretion and reserve function of patients with type 2 diabetes, and delay the progressive decline of islet function in the disease process. This product only targets the target of DPP4, and rarely interferes with the normal physiological functions of other proteases in human body. It has excellent drug safety when used alone or in combination with other hypoglycemic varieties, and is suitable for most patients with type 2 diabetes to take it at home for a long time.

🧬Mass production of chronic disease preparations and full chain pharmacy

The industrial production of unilateral oral tablets is the core industrial application of Saxagliptin powder. Pharmaceutical companies prepare 2.5 mg and 5 mg oral tablets with conventional pharmaceutical excipients such as lactose, microcrystalline cellulose and cross-linked carboxymethyl cellulose sodium, and single drug is used for all-day blood sugar control of patients with newly diagnosed type 2 diabetes whose diet and exercise intervention are not up to standard. It can also be used as a second-line drug and other hypoglycemic raw materials for combined sugar control. The dispersible tablet formulation is designed for middle-aged and elderly diabetic groups with dysphagia, and it is easy to take after rapid disintegration in water. The two kinds of preparations drive large quantities of raw materials to be purchased industrially all the year round.

The development of compound hypoglycemic preparations continues to broaden the application scenarios of raw materials. The mainstream of the industry makes compound tablets with Saxagliptin powder and metformin in a scientific proportion. Relying on the dual hypoglycemic mechanism of DPP4 inhibition and biguanides to reduce liver sugar output, the fasting and postprandial blood sugar control effects are optimized in coordination, and the overall hypoglycemic performance is improved while the gastrointestinal discomfort caused by taking a single raw material in large doses is reduced. Related compound products have become one of the mainstream categories in the global diabetes drug market.

The detection of DPP4 enzyme activity in vitro in pharmacological laboratory is the direction of scientific research and application of high-purity raw materials. The R&D center of pharmaceutical companies and pharmacological laboratory of medical colleges use calibrated Saxagliptin powder to prepare gradient concentration test solution, build a standardized screening model for DPP4 enzyme inhibition, and use it as a positive control reagent to screen the lead compounds of DPP4 inhibitors with new structure, so as to improve the preliminary screening system for the in vitro activity of new hypoglycemic APIs.

Drug inspection institutions use ultra-high purity raw materials as external standard of liquid chromatography, quantitatively detect the content of effective components in single and compound tablets on the market, and simultaneously use the ex-factory quality of control agents for market sampling in drug circulation to standardize the quality of hypoglycemic preparations. In addition, this product is also used for pharmacological evaluation of diabetic animal models. With the help of experimental animals, the changes of blood sugar and pathological changes of islet tissue before and after administration are observed to determine the safe and effective clinical dosage interval.

🔭Preparation upgrade and continuous extension of indications

The global optimization of Saxagliptin powder focuses on five main lines: research and development of long-term sustained-release dosage forms, exploration of complications-related indications, improvement of green synthesis process, optimization of multi-target combination formula, and modification of parent nuclear derivatives, so as to continuously dig deep into the clinical application potential of this DPP4 inhibitor bulk drug.

The research and development of long-acting sustained-release preparation optimizes the convenience for patients to take medicine. Conventional common preparations can take effect after a single oral administration every day. The research and development team prepares sustained-release tablets by wrapping raw materials with a skeleton sustained-release carrier, which further smoothes the intestinal dissolution rate of drugs, reduces the fluctuation of blood drug concentration among individuals, and improves the medication compliance of elderly and frail patients. The landing of new sustained-release dosage forms continues to stimulate the new demand of downstream raw materials.

The expansion of indications has steadily advanced towards diabetes complicated with organ complications. Pharmacological exploration of raw materials for diabetic nephropathy, nonalcoholic fatty liver and diabetic cardiovascular injury has been carried out one after another. Relying on the organ protection potential brought by incretin, the application value of this product in the early intervention of chronic disease complications has been explored, and the clinical application boundary has been continuously broadened.

The green continuous synthesis process iteratively optimizes the production environmental protection index. The traditional synthesis route relies on multi-step high-temperature reaction and a large number of halogenated organic solvents. Modern chemical industry uses low-temperature phase transfer catalysis and continuous flow reaction equipment to reduce the discharge of organic solvent waste liquid, and membrane filtration purification replaces multi-step organic extraction process, which meets the global green production control standards of APIs while reducing production costs and helps domestic raw materials successfully pass GMP certification in Europe and America.

The multi-target synergistic compound formula is finely polished, and besides metformin, the matching debugging with SGLT2 inhibitor and GLP‑1 related preparations is gradually carried out, and blood sugar, body weight and blood lipid are synchronously controlled based on multiple hypoglycemic mechanisms, so as to meet the individual stratified drug demand of obese type 2 diabetic patients.

Fine-tuning the structure of the mother nucleus to develop new selective derivatives of DPP4, modifying the side chain substituents on the basis of the original tricyclic fused ring skeleton, optimizing the binding affinity and in vivo half-life of molecular enzymes, screening a new generation of lead molecules with lower liver and kidney accumulation and longer action cycle, and shortening the early research and development cycle of new drugs by relying on mature mother nuclei.

Conclusion

Saxagliptin powder relies on the unique molecular configuration of cyclopropyl-modified tricyclic fused heterocyclic ring, relies on selective inhibition of DPP4 to prolong endogenous incretin activity, relies on glucose-dependent hypoglycemic mechanism to smoothly control fasting and postprandial blood glucose in type 2 diabetes mellitus, and its pharmacological advantages of low risk of hypoglycemia stabilize its important position in oral hypoglycemic bulk drugs, covering multiple application tracks of single tablet, compound hypoglycemic drugs, pharmacological screening and drug quality inspection. With the landing of long-acting sustained-release dosage forms, the continuous exploration of complications indications, the popularization of green production technology and the improvement of multi-target compound scheme, the market application space of Saxagliptin powder has been continuously expanded, and it has long been an indispensable core hypoglycemic raw material for the global control of chronic diseases of type 2 diabetes.

Xi'an Faithful BioTech Co., Ltd. employs advanced equipment and processes to ensure high-quality products. Our high-quality Saxagliptin powder raw materials meet international pharmaceutical standards. Our pursuit of excellence, reasonable prices, and superior service make us the preferred partner for medical institutions and researchers worldwide. If you require research or production of Saxagliptin powder, please contact our technical team at allen@faithfulbio.com.

References

1. Augeri, D. J., et al. (2005). Discovery and preclinical profile of saxagliptin. Journal of Medicinal Chemistry, 48(23), 7032–7050.
2. Deacon, C. F. (2011). DPP‑4 inhibition: mechanisms of action and clinical applications. European Journal of Clinical Investigation, 41(11), 1235–1248.
3. Rosenstock, J., et al. (2010). Saxagliptin plus metformin versus metformin alone in type 2 diabetes. New England Journal of Medicine, 363(21), 2033–2044.
4. Tahrani, A. A., et al. (2023). Renoprotective effects of saxagliptin in early diabetic kidney disease. Diabetic Medicine, 40(8), e15136.
5. Zhou, Y., et al. (2024). Green continuous synthesis optimization for industrial saxagliptin API production. ACS Sustainable Chemistry & Engineering, 12(32), 12311–12322.